HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.

Abstract
Despite conflicting data regarding its effectiveness, many massive transfusion protocols (MTPs) include recombinant Factor VIIa (rFVIIa) as an adjunct to hemorrhage control. Over a 3-year period, outcome data for massively transfused patients was compared based on administration of rFVIIa as part of a mature MTP. Of 228 MTP activations, 117 patients were candidates for rFVIIa, and, of these, 39 patients received rFVIIa under the MTP. Comparing patients who received rFVIIa with those who did not based on initial packed red blood cell (PRBC) transfusion requirements, there was no difference in mortality for transfusions ≤ 20 units (25 vs 24%, 24-hour; 25 vs 42%, 30-day) or 21 to 30 units (33 vs 47%, 24-hour; 55 vs 50%, 30-day). For initial requirement ≥ 30 units of PRBCs, 24-hour mortality (26 vs 64%, P = 0.02) was significantly decreased in patients that received rFVIIa (n = 19) compared with those who did not (n = 17). These mortality differences were not maintained at 30 days (68 vs 71%). rFVIIa had minimal clinical impact on outcomes for patients requiring less than 30 units of PRBCs. For patients transfused more than 30 units of PRBCs, differences in 24-hour and 30-day mortality suggest that rFVIIa converted early deaths from exsanguination to late deaths from multiorgan failure.
AuthorsBryan C Morse, Christopher J Dente, Erica I Hodgman, Beth H Shaz, Jeffrey M Nicholas, Amy D Wyrzykowski, Jeffrey P Salomone, Gary A Vercruysse, Grace S Rozycki, David V Feliciano
JournalThe American surgeon (Am Surg) Vol. 77 Issue 8 Pg. 1043-9 (Aug 2011) ISSN: 1555-9823 [Electronic] United States
PMID21944521 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa
Topics
  • Adult
  • Blood Transfusion (methods, mortality, standards)
  • Critical Care (standards, trends)
  • Databases, Factual
  • Factor VIIa (administration & dosage)
  • Female
  • Follow-Up Studies
  • Hemorrhage (mortality, prevention & control)
  • Hospital Mortality (trends)
  • Hospitals, University
  • Humans
  • Male
  • Prospective Studies
  • Recombinant Proteins (administration & dosage)
  • Risk Assessment
  • Survival Analysis
  • Time Factors
  • Trauma Centers
  • Treatment Outcome
  • Wounds and Injuries (diagnosis, mortality, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: